Trial reportRespirology case reports2026
Study Protocol of the Endobronchial VAlves for Pneumothorax to Reduce Admission Time (EVAPoRATe) Pilot Multicentre Randomised Clinical Trial.
Trial report in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pneumothorax with persistent air leak (PAL) is a debilitating condition. Patients with PAL often require prolonged chest drainage, with associated complications, such as, hospital-acquired infections, thromboembolism, and deconditioning. Endobronchial valves (EBVs) are an approved bronchoscopic treatment for PAL and may allow earlier chest tube removal and hospital discharge. Current evidence supporting the use of EBV is limited to case series and uncontrolled studies. EBVs are usually used as a last resort when other treatments failed. Whether early referral for EBV placement is feasible and can reduce hospital length of stay in patients with pneumothorax and PAL has not been tested in a randomised controlled trial (RCT). Methods: EVAPoRATe is a prospective, open-labelled, pilot, multi-centre RCT. Forty patients with pneumothorax of any cause and PAL who are unsuitable for or unwilling to undergo surgical management will be randomised 1:1 to the Early EBV Referral arm or the Standard Care arm. Patients in the Early EBV Referral arm will be assessed by an interventional clinician for EBV placement at the earliest feasible time from Day 5 of pneumothorax. Patients allocated to the Standard Care arm will receive conventional management by the attending team; EBV is allowed if clinically appropriate when air leak persists after 12 days. Participants will be followed for 6 months after discharge. Discussion: The primary outcome is the feasibility of the trial protocol, assessed by recruitment rate, adherence to the intervention arm, and retention at follow-up. Secondary outcomes include total hospital length of stay, PAL-related length of stay, interventions for PAL and EBV complications, time to air leak cessation, time to chest drain removal, pneumothorax recurrence, adverse events and serious adverse events, removal of EBVs, performance status, and mortality. This pilot feasibility study will assess whether a future full-scale RCT of EBV for PAL is practical and will provide data to guide protocol refinement and sample size calculation. Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12625000360415; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=388086&isReview=true.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.